Clinical trial
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in…
NCT00171314 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00171314 |
|---|---|
| Title | The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer |
| Official title | The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Zoledronic acid, Letrozole |
| Enrollment | 527 |
| Start date | Mar 1, 2004 |
| Primary completion | Nov 1, 2010 |
| First posted | Sep 15, 2005 |
| Last update posted | Apr 11, 2012 |
| Countries | Argentina, Belgium, France, Italy, Netherlands, Saudi Arabia, South Africa, South Korea, Spain |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: